Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA Negotiations Focus On Review Delays; Firms, FDA See Different Causes

Executive Summary

Industry appears to be showing its strongest hand as PDUFA V negotiations roll along, laying down the cards showing FDA's poor record of meeting user fee goals in recent years
Advertisement

Related Content

CDER’s Automated NDA Assessment Tool May Expand Beyond Clinical Reviews
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model
Vertex's Cystic Fibrosis Drug Kalydeco Could See Speedy Review
CBER Restricts Telephone Contacts With Firms As BIO Presses For Flexibility
CBER Restricts Telephone Contacts With Firms As BIO Presses For Flexibility
PDUFA Old School: Industry Wants User Fees To Get Back To Basics
God Of Gateways: Will FDA's Massive Janus Database Drive Review Efficiency Or Comparative Effectiveness Research?
God Of Gateways: Will FDA's Massive Janus Database Drive Review Efficiency Or Comparative Effectiveness Research?
PDUFA Performance In The FDAAA Era: Over One Third Of Novel 2009 CDER Approvals Took Advantage Of Relaxed User Fee Goal Interregnum
The Good Old Days: FDA's Jenkins Instructs Reviewers To Meet Original User Fee Review Time Standard

Topics

Advertisement
UsernamePublicRestriction

Register

PS052587

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel